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Abstract
Introduction Autologous tumor cell vaccines rely on the
concept of preserving an individual’s own tumorigenic
makeup, expressing its unique set of tumor-associated
antigens as well as antigenic elements from the surround-
ing stroma. These autologous tumor characteristics are
usually presented with an immune adjuvant in the hopes of
enhancing an immune response.
Methods The autologous vaccine we used was composed
of tumor cells combined with BCG and formalin. Animal
safety and toxicity were evaluated using mice tumors for
the immunotherapy. A small number of patients with
advanced stage breast cancer were recruited for an
uncontrolled study, using the vaccine solely or combined
with chemotherapy/radiotherapy.
Results The immunotherapy had shown to be safe in mice
and humans. Upon a 5-year follow-up, the survival rate
was 60 % for the combined treatment.
Conclusions The data suggest that the combined treat-
ment could be a feasible and safe therapeutic strategy.
However, further controlled studies should be conducted.
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Breast cancer is one of the most frequent cancers of women
worldwide, and among the major causes of death. The rate
of breast cancer local relapse is 5–45 % after surgery [1, 2].
Therefore, post-operative radiotherapy or other systemic
treatment is utilized to prevent metastases. There is a need
for adjuvant treatments for tumor and metastasis control
[3].
Improved immune system status might be important in
the prevention of relapse, since certain depression of cell-
mediated immunity may occur during the development of
breast cancer [4]. Chemotherapy and radiotherapy may
further contribute to immunological depression. Therefore,
immunotherapeutic approaches using potential adjuvant
treatments to prevent breast cancer relapse have been
considered.
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Molecular immunology advances have led to the dis-
covery of multiple tumor antigens and pathways, as well as
many other immunoregulatory aspects of breast cancer [5].
Molecular antigenic profiling of neoplastic breast cells
have revealed variable patterns of tumor antigen expres-
sion, posing a challenge on the utilization of single anti-
genic targets for the development of specific
immunotherapies [6, 7]. Conversely, whole cell-based
vaccines, despite their higher, but rare, risk of developing
autoimmune phenomena, may provide a broader load of
antigenic components capable of inducing a broader and
more effective immune response [8–10].
The use of BCG in immunotherapy of various tumors
has been well studied [11]. It is known that BCG phago-
cytosis induces liberation of pro-inflammatory cytokines
with the subsequent development of a Th1 reaction [12,
13]. Similar responses have been revealed in chronic
infectious diseases, such as lepromatous leprosy and
Leishmaniasis. We had found that BCG injected with a
Mycobacterium leprae suspension induced macrophage
activation and subsequent destruction of M. leprae [14, 15].
Additionally, an immunotherapy to treat cutaneous leish-
maniasis was designed, using pasteurized Leishmania
promastigotes with BCG [16]. Both therapies have been
used with positive results. When coupled with the minimal
side effects associated with BCG, the efficacy shown in
these studies supports the use of BCG for other
applications.
Based on these positive experiences and assuming that
the relapse of breast cancer could be partially due to a lack
of appropriate recognition of tumor cells as foreign, the use
of own tumor cells with BCG as an adjuvant
immunotherapy for breast cancer was previously proposed
by Convit and Ulrich [17]. Here, we present the results of
an uncontrolled study of a small number of patients in
advanced stage of the disease, using the individuals’ own
tumor tissue to produce a personalized vaccine. Further-
more, we report the proven safety of this treatment, as well




Fifteen female six-week-old BALB/c mice were divided
into three groups of five (5) animals. Group 1 included
animals treated tumor-free, group 2 untreated tumor-in-
duced, and group 3 treated tumor-induced. For vaccine
preparation, tumors extracted from previously induced
mice were used. Tumors were induced injecting intrader-
mally 8 9 105 4T1 cells per mouse into the mammary
gland. Three doses of the treatment were applied intra-
dermally on their back every week, starting 15 days after
induction when tumors were palpable. Examination of the
general condition of the animals and local reaction in the
area of vaccination was performed every 2 days for
1 month, then twice a week for the next 2 months. Addi-
tionally, female BALB/c mice, hamsters and guinea pigs
were immunized intradermally on their back using a
homogenate from human mammary tumor plus BCG and
formalin. Their general condition and local reaction were
evaluated.
Human study
For the small uncontrolled study, twenty (20) patients in
advanced stages with limited life expectancy were recrui-
ted in a 2-year period. Patients were classified into two
groups according to the treatment to be employed. Group 1
included 6 patients who refused to be treated with standard
treatments and received only immunotherapy. Group 2
included 14 patients treated with both immunotherapy and
chemotherapy/radiotherapy (CT/RT). All patients referred
to this study gave their informed consent, and were aware
that their unidentified data would be used for publication.
This study was duly approved and cleared by the Ethics
Committee of ‘‘Dr. Luis Razetti’’ University Hospital of
Barcelona, Venezuela.
The vaccination procedure included three intradermal
doses of 0.5 ml each, with intervals of 6 weeks between
each dose. Tumor fragments (about 1 g) from patients were
kept in sterile PBS (4.45 mM Na2HPO4, 1.55 mM NaH2-
PO4, 137 mM NaCl, pH 7.2) at -80 C until use. For each
dose, about 0.3–0.4 g of tumor tissue were macerated in
0.6 ml sterile PBS. At the moment of vaccination, the
soluble fraction of the homogenate was mixed with
formaldehyde 36 % at a final concentration of 0.02 % and




All treated tumor-free animals (Group 1) were still alive
within 3 months after induction, while all untreated tumor-
induced animals (Group 2) developed palpable tumors and
died within 45 days after induction. Only two (2) of the
treated tumor-induced animals (Group 3) were still alive
3 months after induction with intangible tumors, repre-
senting a 40 % survival. Both treated groups showed a
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normal growth rate and no local reaction was apparent.
Same results were observed on those mice, hamsters and
guinea pigs that were immunized with the human vaccine.
These observations led us to consider that the
immunotherapy was tolerable for the animals, and that it
was safe and non-toxic.
Human study
Seeking to contrast standard treatment commonly used in
patients with the immunotherapy proposed here, we cal-
culated the estimated overall survival. For the
immunotherapy-only group, the estimated survival was
83.3 %, while for the combined treatment (CT/RT/IT) was
50 %, resulting in an overall survival of 60 % across all
subjects (Fig. 1). The high estimated survival obtained for
the immunotherapy-only group might be due to the small
number of subjects, as compared with the combined treated
group. The calculated overall survival rate (60 %) and that
for the combined treatment (50 %) are similar to the esti-
mated survival reported by Parkin et al. [18] of 67 % for
females with breast cancer in Latin America and the Car-
ibbean. These results indicate that the immunotherapy
proposed (solely or combined) was similarly effective to
the standard treatment, and was considered safe and non-
toxic. To reach a more significant conclusion on its
effectiveness, a more specific analysis of the immunolog-
ical effect involving a higher number of patients is
necessary.
Discussion
For cancer solid tumors, surgery has become the potentially
curative treatment choice available; while for patients with
advanced stages or metastatic disease, this is rarely suffi-
cient [19]. Conventional CT or RT provides acceptable
response rates and improved survival, but they generally
lack tumor specificity and induce cytotoxicity in normal
cells. Alternative therapeutic strategies with fewer side
effects are being studied. The immune system is charac-
terized by high specificity, and takes part in the formation
of a tumor’s microenvironment, contributing to tumor
elimination and progression. In recent years, immunother-
apy has been finely explored as a new form of treatment
[19, 20].
The low antigenicity and depleted capacity of tumor
cells in stimulating antigen presentation are well known, as
well as the inter- and intra-tumoral heterogeneity. There-
fore, vaccination models are usually based on whole
autologous or allogeneic tumor cells; both being used in
clinical trials for breast cancer treatment with variable
reports of improved survival [8, 21–23]. As far as adjuvants
in cancer vaccines, microbes have been utilized for this
purpose as they may break immunological tolerance
toward self-antigens. The use and benefits of BCG as an
adjuvant in the immunotherapy for various types of tumors
have been widely supported [19, 24], and this justified its
use here.
As part of the immunologic approach, we made an
indirect evaluation of the immune system response in all
patients before and after treatment using the intradermal
tuberculin test (PPD for purified protein derivative). We
identified a boost of the immune response in all patients
after treatment, despite the concomitant application of CT
and/or RT (data not shown). Whether this augmentation of
cell-mediated immunity is directly related to the survival
rates observed will need to be established in a larger study.
Although the low number of patients used in this study
might not be statistically significant to make accurate
conclusions, the calculated overall survival rate is similar
to that previously reported for standard treatment [18].
Please note that this equivalency with the overall statistics
was present despite all patients in this uncontrolled trial
having advanced metastatic disease. Therefore, one could
conclude that the combined treatment (IT/CT/RT) is at
least similarly effective as the conventional treatment
alone, but with lower occurrence of side effects, allowing
patients to have a better quality of life. Since our proposed
immunotherapy uses a simple low-cost method of prepa-
ration, it could be a feasible and safe immuno-therapeutic
resource, which coupled with surgery and/or systemic CT/
RT may reduce the recurrence of the disease. This work
Fig. 1 Estimated survival rates. The survival rate upon a 5-year
period was plotted for the immunotherapy only (IT) group (inverted
filled triangle) and the combined treated (CT/RT/IT) group (filled
square), as well as for the overall survival across all subjects (filled
circle). The calculated 5-year survival is indicated for each plot
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may contribute to the recent worldwide efforts to study
immunotherapy as a new alternative treatment for cancer,
but further studies should be performed to reach firmer
conclusions.
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